View this email in your browser

BTP Quarterly Update

May 1, 2020

The mission of the University of Minnesota Brain Tumor Program (UMBTP) is to continually distinguish itself as a national leader in the field of neuro-oncology by combining the principles of outstanding clinical care and education with cutting edge research.

The group consists of many dedicated researchers and clinicians of numerous disciplines and specialties. These disciplines and specialties include - but are not limited to - cancer genetics, neuro-oncology, neurosurgery, pharmacy, biomedical engineering, and veterinary medicine. 

Here's what we've been up to for the last few months:
The 2020 Neuro-Oncology Symposium was postponed due to COVID-19. We plan to reschedule the event and appreciate your patience as we work out all of the details.
Recently, six BTP professors moved their brain tumor laboratories into newly renovated space on the second floor of Malcolm Moos Tower. This Masonic Cancer Center Discovery Lab space will allow unprecedented genomic studies, drug screening, and interaction between basic scientists and clinicians working on nervous system tumors on our campus. The labs were made possible through the Masons' inspiring $25 million pledge acceleration. Members of the Minnesota Masonic Charities board had the opportunity to tour the lab space in early March and meet with the researchers in their labs. Check out photos from the tour.
Logan Spector was highlighted in the article "Playdate Monogamy Is Here to Save Us All" on the website Fatherly, March 19, 2020. 


David Largaespada gave a presentation titled "Using Transposons and Targeted Nucleases to Discover Treatment Targets for Cancer" at the University of Utah, Salt Lake City, UT, February 2020.

David Odde presented a seminar to the Department of Biomedical Engineering at Oregon Health Sciences University, Portland, OR, February 2020.

David Odde presented a seminar to the Department of Mechanical and Aerospace Engineering at Oregon Health Sciences University, Portland, OR, February 2020.

Andrew Venteicher presented at the Forbeck Forums: Leveraging Synthetic Lethality to Treat Cancer, San Diego, CA, February 2020.


David Largaespada has received a grant from Boston Children's Hospital, December 2019, for the project "NF1-related MPNST Patient-Derived Model Program."

Jianfang Ning has received a "Humor to Fight the Tumor" grant from the Humor to Fight the Tumor Foundation, 2020.

David Odde has received an R01 grant from the NIH, 2020, for the project "Investigation of the Role of UNC-45A in Paclitaxel-Mediated Microtubule Stability."


No new clinical trials reported.


Shamsan GA, Odde DJ. "Emerging Technologies in Mechanotransduction Research." Curr Opin Chem Biol. 2019 Dec;53:125-130. doi: 10.1016/j.cbpa.2019.08.002. PMID: 31618703.

Jules-Dole N, Uribe-Cardenas R, McReynolds LJ, Borden L, Chambers S, Bell WR, Ahn ES, Raabe E, Salpekar JA. "Psychosis Remitted after Ependymoma Resection in a School-Aged Child." J Neuropsychiatry Clin Neurosci. 2019 Dec 4:appineuropsych19070147. doi: 10.1176/appi.neuropsych.19070147. Epub ahead of print. PMID: 31795806.

Horta E, Bongiorno C, Ezzeddine M, Neil EC. "Neurotoxicity of Antibodies in Cancer Therapy: A Review." Clin Neurol Neurosurg. 2020 Jan;188:105566. doi: 10.1016/j.clineuro.2019.105566. PMID: 31731087.

Smeester BA, Slipek NJ, Pomeroy EJ, Bomberger HE, Shamsan GA, Peterson JJ, Crosby MR, Draper GM, Becklin KL, Rahrmann EP, McCarthy JB, Odde DJ, Wood DK, Largaespada DA, Moriarity BS. "SEMA4C Is a Novel Target to Limit Osteosarcoma Growth, Progression, and Metastasis." Oncogene. 2020 Jan;39(5):1049-1062. doi: 10.1038/s41388-019-1041-x. PMID: 31582836.

Martin AM*, Bell WR*, Yuan M, Harris L, Poore B, Arnold A, Engle EL, Asnaghi L, Lim M, Raabe EH, Eberhart CG. "PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status." J Neuropathol Exp Neurol. 2020 Jan 1;79(1):74-85. doi: 10.1093/jnen/nlz119. PMID: 31819973. (*co-first author)

Xiong Z, Ampudia Mesias E, Pluhar GE, Rathe SK, Largaespada DA, Sham YY, Moertel CL, Olin MR. "CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy." Clin Cancer Res. 2020 Jan 1;26(1):232-241. doi: 10.1158/1078-0432.CCR-19-2234. PMID: 31624103.

Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP. "Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma Is Independent of Base Excision Repair." Clin Cancer Res. 2020 Jan 3. doi: 10.1158/1078-0432.CCR-19-2000. Epub ahead of print. PMID: 31900275.

Koga T, Chaim IA, Benitez JA, Markmiller S, Parisian AD, Hevner RF, Turner KM, Hessenauer FM, D'Antonio M, Nguyen ND, Saberi S, Ma J, Miki S, Boyer AD, Ravits J, Frazer KA, Bafna V, Chen CC, Mischel PS, Yeo GW, Furnari FB. "Longitudinal Assessment of Tumor Development Using Cancer Avatars Derived from Genetically Engineered Pluripotent Stem Cells." Nat Commun. 2020 Jan 28;11(1):550. doi: 10.1038/s41467-020-14312-1. PMID: 31992716; PMCID: PMC6987220.

Ning J, Wakimoto H. "Therapeutic Application of PARP Inhibitors in Neuro-Oncology." Trends Cancer. 2020 Feb;6(2):147-159. doi: 10.1016/j.trecan.2019.12.004. PMID: 32061304.

Zhu Z, Mesci P, Bernatchez JA, Gimple RC, Wang X, Schafer ST, Wettersten HI, Beck S, Clark AE, Wu Q, Prager BC, Kim LJY, Dhanwani R, Sharma S, Garancher A, Weis SM, Mack SC, Negraes PD, Trujillo CA, Penalva LO, Feng J, Lan Z, Zhang R, Wessel AW, Dhawan S, Diamond MS, Chen CC, Wechsler-Reya RJ, Gage FH, Hu H, Siqueira-Neto JL, Muotri AR, Cheresh DA, Rich JN. "Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis." Cell Stem Cell. 2020 Feb 6;26(2):187-204.e10. doi: 10.1016/j.stem.2019.11.016. PMID: 31956038.

Beckmann PJ, Largaespada DA. "Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities." Int J Mol Sci. 2020 Feb 10;21(3):1172. doi: 10.3390/ijms21031172. PMID: 32050713; PMCID: PMC7036786.

Prahl LS, Stanslaski MR, Vargas P, Piel M, Odde DJ. "Predicting Confined 1D Cell Migration from Parameters Calibrated to a 2D Motor-Clutch Model." Biophys J. 2020 Feb 25:S0006-3495(20)30163-6. doi: 10.1016/j.bpj.2020.01.048. Epub ahead of print. PMID: 32145191.

Duckett MM, Phung SK, Nguyen L, Khammanivong A, Dickerson E, Dusenbery K, Lawrence J. "The Adrenergic Receptor Antagonists Propranolol and Carvedilol Decrease Bone Sarcoma Cell Viability and Sustained Carvedilol Reduces Clonogenic Survival and Increases Radiosensitivity in Canine Osteosarcoma Cells." Vet Comp Oncol. 2020 Mar;18(1):128-140. doi: 10.1111/vco.12560. PMID: 31778284.

Parikh BB, Neil EC. "Evolving Strategies to Potentially Further Optimize Surgical Interventions in Brain Cancer." Curr Oncol Rep. 2020 Mar 6;22(4):32. doi: 10.1007/s11912-020-0896-x. PMID: 32140793.

Borgatti A, Fieberg A, Winter AL, Stuebner K, Taras E, Todhunter D, Masyr A, Rendhal A, Vallera DA, Koopmeiners JS, Modiano JF. "Impact of Repeated Cycles of EGF Bispecific Angiotoxin (eBAT) Administered at a Reduced Interval from Doxorubicin Chemotherapy in Dogs with Splenic Hemangiosarcoma." Vet Comp Oncol. 2020 Mar 18. doi: 10.1111/vco.12590. Epub ahead of print. PMID: 32187827.

Rennert RC, Khan U, Bartek J, Tatter SB, Field M, Toyota B, Fecci PE, Judy K, Mohammadi AM, Landazuri P, Sloan AE, Kim AH, Leuthardt EC, Chen CC. "Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization." Neurosurgery. 2020 Apr 1;86(4):538-547. doi: 10.1093/neuros/nyz141. PMID: 31076762.

Williams LA, Moertel CL, Richardson M, Marcotte EL. "Incidence of Second Malignancies in Individuals Diagnosed with Malignant Peripheral Nerve Sheath Tumors." J Neurooncol. 2020 Apr 1. doi: 10.1007/s11060-020-03478-9. Epub ahead of print. PMID: 32239432.

Smeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N, Yamamoto K, Peterson JJ, Rathe SK, Mills LJ, Hudson WA, Crosby MR, Wang M, Rahrmann EP, Moriarity BS, Largaespada DA. "PLX3397 Treatment Inhibits Constitutive CSF1R-Induced Oncogenic ERK Signaling, Reduces Tumor Growth, and Metastatic Burden in Osteosarcoma." Bone. 2020 Apr 3:115353. doi: 10.1016/j.bone.2020.115353. Epub ahead of print. PMID: 32251854.

Ricard JA, Charles R, Yohe S, Bell WR, Flanagan ME. "Epstein Virus Barr Positive Diffuse Large B-cell Lymphoma Associated with Hemophagocytic Lymphohistiocytosis." Journal of Neuropathology and Experimental Neurology. Accepted 2019 Nov.

Past Events

The Discovery Labs opened in Moos 2 this past winter, where 6 BTP professors now have their labs.

Upcoming Events

May 14 - BTP Data Club, Joseline Haizel-Cobbina, MD
June 11 - BTP Data Club,
Renata Saha
July 9 - BTP Data Club,
Florina Grigore
August 13 - BTP Data Club, TBD

Highlights & Recognitions

The Brain Tumor Program is excited to welcome five new members to our research team:
Submit content for next newsletter
Copyright © 2019 University of Minnesota Brain Tumor Program, All rights reserved.
You are receiving this email because you opted in at our website, at a recent event, or are a member/affiliate of a BTP lab at the University of Minnesota. 
To ensure continued delivery, add to your safe senders list or address book.

Our mailing address is:
Brain Tumor Program
2231 6th St SE
CCRB 3-115
Minneapolis, MN 55455


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
University of Minnesota Brain Tumor Program · 420 Delaware St. SE · MMC 484 · Minneapolis, MN 55455-0001 · USA

Email Marketing Powered by Mailchimp